Search

Your search keyword '"Pratt, Nicole L."' showing total 549 results
Start Over Author "Pratt, Nicole L."
549 results on '"Pratt, Nicole L."'

63. Does a Prescription-based Comorbidity Index Correlate with the American Society of Anesthesiologists Physical Status Score and Mortality After Joint Arthroplasty? A Registry Study

Author

Kerr, Mhairi M., primary, Graves, Stephen E., additional, Duszynski, Katherine M., additional, Inacio, Maria C., additional, de Steiger, Richard N., additional, Harris, Ian A., additional, Ackerman, Ilana N., additional, Jorm, Louisa R., additional, Lorimer, Michelle F., additional, Gulyani, Aarti, additional, and Pratt, Nicole L., additional

Published
2021
Full Text
View/download PDF

70. Suitability of databases in the Asia‐Pacific for collaborative monitoring of vaccine safety

Author

Duszynski, Katherine M., primary, Stark, James H., additional, Cohet, Catherine, additional, Huang, Wan‐Ting, additional, Shin, Ju‐Young, additional, Lai, Edward Chia‐Cheng, additional, Man, Kenneth K. C., additional, Choi, Nam‐Kyong, additional, Khromava, Alena, additional, Kimura, Tomomi, additional, Huang, Kui, additional, Watcharathanakij, Sawaeng, additional, Kochhar, Sonali, additional, Chen, Robert T., additional, and Pratt, Nicole L., additional

Published
2021
Full Text
View/download PDF

80. Impact of a patient-specific national programme aimed at increasing the use of emollient moisturisers to reduce the risk of skin tears: a longitudinal cohort study

Author

Moffat, Anna K, primary, Westaway, Kerrie P, additional, Apajee, Jemisha, additional, Frank, Oliver, additional, Shute, Russell, additional, Weston, Clare, additional, Blacker, Natalie, additional, Le Blanc, Vanessa T, additional, Kalisch Ellett, Lisa M, additional, Pratt, Nicole L, additional, and Roughead, Elizabeth Ellen, additional

Published
2020
Full Text
View/download PDF

83. Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome

Author

Lim, Renly, primary, Bereznicki, Luke, additional, Corlis, Megan, additional, Kalisch Ellett, Lisa M, additional, Kang, Ai Choo, additional, Merlin, Tracy, additional, Parfitt, Gaynor, additional, Pratt, Nicole L, additional, Rowett, Debra, additional, Torode, Stacey, additional, Whitehouse, Joseph, additional, Andrade, Andre Q, additional, Bilton, Rebecca, additional, Cousins, Justin, additional, Kelly, Lan, additional, Schubert, Camille, additional, Williams, Mackenzie, additional, and Roughead, Elizabeth Ellen, additional

Published
2020
Full Text
View/download PDF

84. Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study

Author

Brauer, Ruth, primary, Wong, Ian Chi Kei, additional, Man, Kenneth KC, additional, Pratt, Nicole L, additional, Park, Rae Woong, additional, Cho, Soo-Yeon, additional, Li, Yu-Chuan (Jack), additional, Iqbal, Usman, additional, Nguyen, Phung-Anh Alex, additional, and Schuemie, Martijn, additional

Published
2020
Full Text
View/download PDF

86. CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study

Author

Sidhu, Verinder Singh, primary, Graves, Steven E, additional, Buchbinder, Rachelle, additional, Naylor, Justine Maree, additional, Pratt, Nicole L, additional, de Steiger, Richard S, additional, Chong, Beng H, additional, Ackerman, Ilana N, additional, Adie, Sam, additional, Harris, Anthony, additional, Hansen, Amber, additional, Cripps, Maggie, additional, Lorimer, Michelle, additional, Webb, Steve, additional, Clavisi, Ornella, additional, Griffith, Elizabeth C, additional, Anandan, Durga, additional, O'Donohue, Grace, additional, Kelly, Thu-Lan, additional, and Harris, Ian A, additional

Published
2019
Full Text
View/download PDF

88. The Australian Orthopaedic Association National Joint Replacement Registry

Author

Graves, Stephen E., Davidson, David, Ingerson, Lisa, Ryan, Philip, Griffith, Elizabeth C., McDermott, Brian F.J., McElroy, Heather J., and Pratt, Nicole L.

Subjects
Information management, Information accessibility, Health
Abstract

The reasons to implement a National Joint Replacement Registry by the Australian Orthopaedic Association are outlined. The Registry aims to provide quality demographic information on the practice of joint-replacement surgery, improve outcomes, and establish a mechanism of audit for hospitals and individual surgeons.

Published
2004

90. Heart failure after conventional metal-on-metal hip replacements

Author

Gillam, Marianne H, Pratt, Nicole L, Inacio, Maria C S, Roughead, Elizabeth E, Shakib, Sepehr, Nicholls, Stephen J, and Graves, Stephen E

Subjects
musculoskeletal diseases, Aged, 80 and over, Heart Failure, Male, Hip, Arthroplasty, Replacement, Hip, Incidence, Australia, Prosthesis Design, Prosthesis Failure, Survival Rate, Metal-on-Metal Joint Prostheses, Humans, Female, Hip Prosthesis, Registries, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Background and purpose — It is unclear whether metal particles and ions produced by mechanical wear and corrosion of hip prostheses with metal-on-metal (MoM) bearings have systemic adverse effects on health. We compared the risk of heart failure in patients with conventional MoM total hip arthroplasty (THA) and in those with metal-on-polyethylene (MoP) THA. Patients and methods — We conducted a retrospective cohort study using data from the Australian Government Department of Veterans’ Affairs health claims database on patients who received conventional THA for osteoarthritis between 2004 and 2012. The MoM THAs were classified into groups: Articular Surface Replacement (ASR) XL Acetabular System, other large-head (LH) (> 32 mm) MoM, and small-head (SH) (≤ 32 mm) MoM. The primary outcome was hospitalization for heart failure after THA. Results — 4,019 patients with no history of heart failure were included (56% women). Men with an ASR XL THA had a higher rate of hospitalization for heart failure than men with MoP THA (hazard ratio (HR) = 3.2, 95% CI: 1.6–6.5). No statistically significant difference in the rate of heart failure was found with the other LH MoM or SH MoM compared to MoP in men. There was no statistically significant difference in heart failure rate between exposure groups in women. Interpretation — An association between ASR XL and hospitalization for heart failure was found in men. While causality between ASR XL and heart failure could not be established in this study, it highlights an urgent need for further studies to investigate the possibility of systemic effects associated with MoM THA.

Published
2016

97. A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly

Author

Pratt Nicole L, Ewald Ben, Roughead Elizabeth E, Ramsay Emmae N, and Ryan Philip

Subjects
Medicine (General), R5-920
Abstract

Abstract Background To determine the suitability of using the self-controlled case series design to assess improvements in health outcomes using the effectiveness of beta blockers for heart failure in reducing hospitalisations as the example. Methods The Australian Government Department of Veterans' Affairs administrative claims database was used to undertake a self-controlled case-series in elderly patients aged 65 years or over to compare the risk of a heart failure hospitalisation during periods of being exposed and unexposed to a beta blocker. Two studies, the first using a one year period and the second using a four year period were undertaken to determine if the estimates varied due to changes in severity of heart failure over time. Results In the one year period, 3,450 patients and in the four year period, 12, 682 patients had at least one hospitalisation for heart failure. The one year period showed a non-significant decrease in hospitalisations for heart failure 4-8 months after starting beta-blockers, (RR, 0.76; 95% CI (0.57-1.02)) and a significant decrease in the 8-12 months post-initiation of a beta blocker for heart failure (RR, 0.62; 95% CI (0.39, 0.99)). For the four year study there was an increased risk of hospitalisation less than eight months post-initiation and significant but smaller decrease in the 8-12 month window (RR, 0.90; 95% CI (0.82, 0.98)). Conclusions The results of the one year observation period are similar to those observed in randomised clinical trials indicating that the self-controlled case-series method can be successfully applied to assess health outcomes. However, the result appears sensitive to the study periods used and further research to understand the appropriate applications of this method in pharmacoepidemiology is still required. The results also illustrate the benefits of extending beta blocker utilisation to the older age group of heart failure patients in which their use is common but the evidence is sparse.

Published
2011
Full Text
View/download PDF

98. Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study.

Author

Ha-Lim Jeon, Seong Jun Byun, Pratt, Nicole L., Sultana, Janet, Sang Jun Park, and Ju-Young Shin

Abstract

Aims To identify the association between ranibizumab and risk of stroke and acute myocardial infarction (AMI) in patients with exudative age-related macular degeneration (AMD). Methods We identified patients aged =45 years who received ranibizumab for exudative AMD from the Korean National Health Insurance database. Of these, we selected patients suffering stroke or AMI for the self-controlled case series. We estimated incidence rate ratios (IRR) for stroke or AMI by comparing incidence rates of ranibizumab-exposed periods to that of baseline using conditional Poisson regression. The risks of haemorrhagic and ischaemic strokes were also calculated separately. Results Among 33 134 patients receiving ranibizumab, 2397 patients had stroke or AMI. The risk of stroke (IRR=0.83, 95% CI 0.75 to 0.91) was not increased during the overall exposed period; however, there was a marginally elevated risk in =57 days exposed period (IRR=1.14, 95% CI 1.001 to 1.31). When analysing by the types of stroke, no increased risks of haemorrhagic (IRR=1.01, 95% CI 0.80 to 1.26) and ischaemic stroke (IRR=0.78, 95% CI 0.71 to 0.86) were observed during the exposed period, although the risks of ischaemic and haemorrhagic stroke were slightly elevated during =57 days exposed period. We could not find an association between ranibizumab and AMI. Conclusions Ranibizumab intravitreal injections did not increase the overall risk of stroke or AMI. Although the cardiovascular risk in patient receiving ranibizumab seems to be low, continuous monthly use of ranibizumab for high-risk patients should be judged carefully. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

99. Prior experience with cardiovascular medicines predicted longer persistence in people initiated to combinations of antihypertensive and lipid-lowering therapies: findings from two Australian cohorts

Author

Bartlett,Louise E, Pratt,Nicole L, Roughead,Elizabeth E, Bartlett,Louise E, Pratt,Nicole L, and Roughead,Elizabeth E

Abstract

Louise E Bartlett, Nicole L Pratt, Elizabeth E Roughead Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia Purpose: Many studies of persistence involving fixed dose combinations (FDCs) of cardiovascular medicines have not adequately accounted for a user’s prior experience with similar medicines. The aim of this research was to assess the effect of prior medicine experience on persistence to combination therapy. Patients and methods: Two retrospective cohort studies were conducted in the complete Pharmaceutical Benefits Scheme prescription claims dataset. Initiation and cessation rates were determined for combinations of: ezetimibe/statin; and amlodipine/statin. Initiators to combinations of these medicines between April and September 2013 were classified according to prescriptions dispensed in the prior 12 months as either: experienced to statin or calcium channel blocker (CCB); or naïve to both classes of medicines. Cohorts were stratified according to formulation initiated: FDC or separate pill combinations (SPC). Cessation of therapy over 12 months was determined using Kaplan–Meier survival analysis. Risk of cessation, adjusted for differences in patient characteristics was assessed using Cox proportional hazard models. Results: There were 12,169 people who initiated combinations of ezetimibe/statin; and 26,848 initiated combinations of amlodipine/statin. A significant proportion of each cohort were naïve initiators: ezetimibe/statin cohort, 1,964 (16.1%) of whom 81.9% initiated a FDC; and amlodipine/statin cohort, 5,022 (18.7%) of whom 55.4% initiated a FDC. Naïve initiators had a significantly higher risk of ceasing therapy than experienced initiators regardless of formulation initiated: ezetimibe/statin cohort, naïve FDC versus experienced FDC HR=3.0 (95% CI 2.8, 3.3) a

Published
2018

100. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting.

Author

Pratt, Nicole L., Mack, Christina D., Meyer, Anne Marie, Davis, Kourtney J., Hammill, Bradley G., Hampp, Christian, Setoguchi, Soko, Raman, Sudha R., Chun, Danielle S., Stürmer, Til, and Lund, Jennifer L.

Abstract

Purpose The purpose of this paper is to provide guidance on the evaluation of data linkage quality through the development of a checklist for reporting key elements of the linkage process. Methods: Responding to a call for manuscripts from the International Society for Pharmacoepidemiology (ISPE), a working group including international representation from the academic, industry, and contract research, and regulatory sectors was formed to develop a checklist for evaluation of data linkage performance and reporting data linkage specifically for pharmacoepidemiologic research. This checklist expands on the reporting of studies conducted using observational routinely collected health data specific to pharmacoepidemiology (RECORD‐PE) guidelines. Results: A key aspect of data linkage evaluation for pharmacoepidemiology is to articulate how a linkage process was performed and its accuracy in terms of validation and verification of the resulting linked data. This study generates a checklist, which covers domains including data sources, linkage variables, linkage methods, linkage results, and linkage evaluation. For each domain, specific recommendations provide a clear and transparent assessment of the linkage process. Conclusions: Linking data sources can help to enrich analytic databases to more accurately define study populations, enable adjustment for confounding, and improve the capture of health outcomes. Clear and transparent reporting of data linkage processes will help to increase confidence in the evidence generated from these data by allowing researchers and end users to critically assess the potential for bias owing to the data linkage process. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results